A phase Ila clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild -type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

被引：0

作者：

Meric-Bernstam, F. ^{[1
]}

Somaiah, N. ^{[2
]}

DuBois, S. G. ^{[3
,4
]}

Dumbrava, E. E. Ileana ^{[1
]}

Shapiro, G. I. ^{[4
]}

Patel, M. R. ^{[5
]}

Goel, S. ^{[6
]}

Bauer, T. ^{[7
]}

Pinchasik, D. ^{[8
]}

Annis, A. ^{[9
]}

Aivado, M. ^{[10
]}

Vukovic, V. ^{[11
]}

Saleh, M. ^{[12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Sarcoma Med Oncol, Houston, TX 77030 USA

[3] Dana Farber & Boston Childrens, Pediat Oncol, Boston, MA USA

[4] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA

[5] Florida Canc Specialists & Res Inst, Med Oncol, Sarasota, FL USA

[6] Montefiore Med Ctr, Med Oncol, Eastchester Albert Einstein Canc Ctr, East Campus,Med Pk, New York, NY USA

[7] Sarah Cannon Res Inst, Drug Dev, Nashville, TN USA

[8] Aileron Therapeut Inc, Clin Dev, Cambridge, MA USA

[9] Aileron Therapeut Inc, Res, Watertown, MA USA

[10] Aileron Therapeut Inc, Res & Drug Dev, Watertown, MA USA

[11] Aileron Therapeut Inc, Clin & Med, Watertown, MA USA

[12] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Hematol Oncol, Birmingham, AL USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

475P

引用

页码：179 / +

页数：2

共 50 条

[1] p53 mutation and MDM2 amplification in inflammatory myofibroblastic tumours
Yamamoto, H
Oda, Y
Saito, T
Sakamoto, A
Miyajima, K
Tamiya, S
Tsuneyoshi, M
HISTOPATHOLOGY, 2003, 42 (05) : 431 - 439
[2] Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
Wunder, JS
Eppert, K
Burrow, SR
Gogkoz, N
Bell, RS
Andrulis, IL
ONCOGENE, 1999, 18 (03) : 783 - 788
[3] Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
Jay S Wunder
Kolja Eppert
Sarah R Burrow
Nalan Gogkoz
Robert S Bell
Irene L Andrulis
Oncogene, 1999, 18 : 783 - 788
[4] Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification
Lyle, Pamela L.
Bridge, Julia A.
Simpson, Jean F.
Cates, Justin M.
Sanders, Melinda E.
HISTOPATHOLOGY, 2016, 68 (07) : 1040 - 1045
[5] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Saleh, Mansoor N.
Patel, Manish R.
Bauer, Todd M.
Goel, Sanjay
Falchook, Gerald S.
Shapiro, Geoffrey, I
Chung, Ki Y.
Infante, Jeffrey R.
Conry, Robert M.
Rabinowits, Guilherme
Hong, David S.
Wang, Judy S.
Steidl, Ulrich
Naik, Gurudatta
Guerlavais, Vincent
Vukovic, Vojislav
Annis, D. Allen
Aivado, Manuel
Meric-Bernstam, Funda
CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
[6] CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, Anusha
Dickmanns, Antje
Najafova, Zeynab
Johnsen, Steven A.
Dobbelstein, Matthias
CELL DEATH & DISEASE, 2018, 9
[7] CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Anusha Sriraman
Antje Dickmanns
Zeynab Najafova
Steven A. Johnsen
Matthias Dobbelstein
Cell Death & Disease, 9
[8] Amplification of CDK4 and MDM2 is associated with atypical clinical features in high risk neuroblastoma patients
Fransson, Susanne M.
Kryh, Hanna
Javanmardi, Niloufar
Ambros, Inge M.
Berbegall, Ana P.
Ora, Ingrid
Noguera, Rosa
Asmundsson, Jurate
Sandstedt, Bengt
Ambros, Peter F.
Kogner, Per
Martinsson, Tommy
CANCER RESEARCH, 2016, 76
[9] ACCUMULATION OF WILD-TYPE P53 PROTEIN IN ASTROCYTOMAS IS NOT MEDIATED BY MDM2 GENE AMPLIFICATION
RUBIO, MP
LOUIS, DN
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1993, 52 (03): : 323 - 323
[10] Co-amplification of CDK4 and MDM2 plus HMGA2 fusion in a patient with myogenic differentiation dedifferentiated liposarcoma.
Huang, Gang
Li, Xianan
Wang, Chunyang
He, Qifan
Wang, Xiaojuan
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →